REGN5093-M114 is a bispecific antibody-drug conjugate (ADC) that targets two epitopes of the MET receptor tyrosine kinase, effectively inhibiting NSCLC cell proliferation and demonstrating antitumor activity in mouse models. REGN5093-M114 is composed of the human monoclonal anti-MET antibody Davutamig and a tubulin-inhibiting linker-payload.
